1. Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

2. Program Themes

3. Case Study: 42-Year-Old Woman, 6-Month Follow-Up of Her PAH

4. Clinical Course

5. Clinical Course January 2015

6. Therapies Targeting the PGI2 Pathway

7. Therapeutic Decision January 2015

8. Today’s Evaluation

9. Adherence With Inhaled Prostanoids

10. GRIPHON Treatment Effect by Subgroup

11. Right Heart Catheterization

12. Transitioning From Inhaled to Oral Prostacyclin Pathway Agent

13. Transition From Inhaled Treprostinil to Oral Selexipag

14. AMBITION Ambrisentan + Tadalafil vs Monotherapy in Treatment-Naive Patients With PAH

15. Initial Triple Therapy

16. Conclusions

17. Abbreviations